The complement system is an important part of innate immunity; however, as with other parts of the immune system, the complement system can become pathologically activated and create or worsen disease. Anticomplement reagents have been studied for several years, but only recently have they emerged as a viable therapeutic tool. Here, we describe the role of the complement system in a wide array of diseases, as well as the use of anticomplement therapy as treatment for these diseases in animal models and in human clinical trials. Specifi cally, we will discuss the role of anticomplement therapy in paroxysmal nocturnal hemoglobinuria, glomerulonephritis, and heart disease, including coronary artery disease, myocardial infarction, and coronary revascularization procedures such as percutaneous coronary angioplasty and coronary artery bypass graft surgery.
Introduction
The complement system, as a part of innate immunity, carries out a wide array of functions, including protection against foreign organisms, removal of immune complexes from the circulation, and clean-up of cellular debris which accumulates over time. The complement system also plays a signifi cant role in the initiation and propagation of the infl ammatory response. Besides its benefi cial effect, though, the complement system can also play a detrimental role in many pathologic conditions.
The complement system comprises several plasma and cell surface proteins, including complement regulatory proteins. When these complement regulatory proteins do not function properly, the complement system can become improperly activated and cause tissue damage. Over the last several years, a signifi cant amount of work has been done to study complement activation in certain disease states and whether there is any role for complement inhibition in the treatment of these diseases. In this paper, we will review the function and regulation of the complement system, give a brief description of various complement inhibitors, and discuss the recent use of anticomplement therapeutics in specifi c diseases, namely paroxysmal nocturnal hemoglobinuria, glomerulonephritis, and heart disease, including coronary artery disease, myocardial infarction, and cardiac surgery requiring the use of cardiopulmonary bypass.
Overview of the complement system Activation of the complement system
The complement system comprises more than 30 plasma proteins, most of which are synthesized by the liver. The complement system acts through three major pathways, the classical pathway, activated by antigen-antibody complexes; the alternative pathway, activated spontaneously by attachment of C3b to a particular surface; and the lectin pathway, activated by the binding of mannan-binding lectins to carbohydrate ligands on the surface of pathogens (Figure 1 ) (Janeway et al 1999; Qin and Gao 2006; Cummings et al 2007; Oksjoki et al 2007) . The central convergence point of all three pathways is the formation of a C3 convertase on the surface of a particular cell. With the formation of a functioning C3 convertase, complement is able to carry out its effector functions (Figure 2 ).
In the classical pathway, C1q, one of the subunits of C1, fi rst binds to the F c domains of antibodies attached to their antigen. Another subunit of C1, C1r, cleaves and activates the third subunit of C1, C1s. Activated C1s cleaves C4 and C2 to form C4b and C2b, respectively, which then combine to form the C3 convertase of the classical complement pathway (Figure 1) . Similarly, in the lectin pathway, cleavage of C4 and C2 allow formation of the C3 convertase. In the alternative pathway, C3 is spontaneously cleaved to C3a and C3b. C3b covalently binds to cell surfaces and with the help of factor B (FB) and factor D (FD) can form the C3bBb complex, which is the alternative pathway's C3 convertase (Figure 1 ).
The function of the C3 convertase in all three pathways is to further cleave C3, producing C3a, one of the two major anaphylatoxins of the complement system, and C3b, a potent opsonin. Binding of several C3b molecules to cells and other debris marks them for phagocytosis by macrophages. Propagation of complement activation by the C3 convertase results in the generation of a C5 convertase on cell surfaces. The function of the C5 convertase is to cleave C5 to C5a and C5b. C5a is the other anaphylatoxin and is much more potent than C3a. As anaphylatoxins, C3a and C5a are able to recruit neutrophils to areas of infl ammation and damage. C5b is subsequently able to bind to C6, C7, C8, and C9 to form the membrane attack complex . The C5b-9 complex is able to disrupt the phospholipid bilayer of the cell membrane, leading to loss of cellular homeostasis and eventual cell death (Figure 2) . Thus, the three main functions of the complement system are opsonization of pathogens or other molecules, which targets them for eventual destruction, augmentation of infl ammation by the recruitment of infl ammatory cells via the anaphylatoxins C3a and C5a, and direct killing of cells by the formation of MACs (Figure 2 ).
Anticomplement therapy

Regulation of the complement system
Because the complement system has such a potent ability to cause cellular damage, it is extensively regulated both in the fl uid phase and on cell surfaces. We will briefl y describe the major complement regulatory proteins.
In the classical pathway, one of the main complement regulatory proteins is C1 inhibitor (C1-INH), which binds to the C1r:C1s complex and causes it to dissociate from C1q, thus preventing activation of the complement system. The function of the other major complement regulatory proteins can be categorized under two major activities: (1) breaking up the C3 convertase, termed decay-accelerating activity and (2) cleavage of either C3b or C4b to their inactive forms, iC3b and iC4b, respectively, termed membrane co-factor activity. Proteins with decay-accelerating activity which regulate the classical pathway include C4-binding protein (C4bp), complement receptor 1 (CR1), and decay-accelerating factor (DAF) or CD55. Proteins with decay-accelerating activity which regulate the alternative pathway include CR1, factor H (FH), and DAF ( Figure 1 ).
All membrane co-factor activity relies on the function of a serine protease known as factor I (FI). Factor I, in turn, requires at least one of several potential co-factors to degrade C3b and C4b. For the classical pathway, proteins with membrane co-factor activity include C4bp, CR1, and membrane co-factor protein (MCP), while those for the alternative pathway are CR1, FH, and MCP.
Another important regulatory protein is CD59, also known as protectin. CD59 prevents formation of the C5b-9 complex (MAC) on cell surfaces and is highly expressed on cell membranes throughout the body.
Development of complement inhibitors
The fi rst complement inhibitor described in the scientifi c literature was cobra venom factor (CVF). The anticomplement activity of cobra venom was described by Flexner and Noguchi in 1903 (Flexner and Noguchi 1903) . It was not until the late 1960's and early 1970's that the component of cobra venom responsible for its anticomplement activity was recognized (Gewurz et al 1967; Maillard and Zarco 1968; Cochrane et al 1970; Phillips 1970; Muller-Eberhard and Fjellstrom 1971) . CVF binds to mammalian FB in plasma and after cleavage of FB by FD, a stable, soluble C3 convertase is produced, the CVF-Bb complex (Cooper 1973) . The CVF-Bb complex consumes C3 in the plasma very effi ciently; in fact, a single injection of CVF can completely eliminate complement activity for 24-72 hours in certain animal models (Morgan and Harris 2003) .
One of the fi rst synthetic molecules to be developed for anticomplement therapy was nafamastat mesilate, also known as FUT-175. This molecule inhibits C1r, C1s, C3 convertase, C5 convertase, and FD (Fujii and Hitomi 1981; Inagi et al 1991) . Nafamastat mesilate is not entirely complement-specifi c, however, and can inhibit several other plasma proteases (Hitomi and Fujii 1982 C5b,6,7,8,9 (C5b-9) Membrane attack complex C4b,2b C4b,2b C3b,Bb Figure 2 The complement system and its effectors.
is composed of only 13 amino acid residues, binds to C3 and inhibits its cleavage by C3 convertase (Sahu et al 1996) . Molecules blocking C1q in vitro have also been obtained from random peptide libraries (Roos et al 2001) .
Interestingly, heparin has long been known to possess anticomplement properties (Weiler et al 1978) . Its effects include binding to and subsequent inactivation of C1, inhibition of MAC assembly, and blockage of the formation of C3 convertase (Baker et al 1975; Hughes-Jones and Gardner 1978; Almeda et al 1983; Weiler 1983) .
Another category of complement inhibitors is recombinant proteins that are engineered using genes encoding membrane complement regulatory proteins. These recombinant proteins have been genetically modifi ed to make them soluble so that they inhibit complement activation in the fl uid phase. One of the fi rst recombinant complement inhibitors was soluble CR1 (sCR1), also known as TP10. Weisman et al developed this molecule, which comprises the entire extracellular domain of CR1, and showed that it inhibited formation of C3 and C5 convertases in vivo (Weisman et al 1990a (Weisman et al , 1990b . Soluble recombinant MCP and DAF have also been developed and have been shown to inhibit complement both in vitro and in vivo (Moran et al 1992; Christiansen et al 1996) . A hybrid molecule named complement activation blocker-2 (CAB-2) was designed by fusing the functional domains of MCP and DAF (Higgins et al 1997) . In vitro CAB-2 was shown to inhibit complement activation (Kroshus et al 2000) .
Another logical approach to inhibition of the complement system is to use a blocking antibody against one of the many interacting complement proteins. N19-8, the fi rst anticomplement monoclonal blocking antibody developed, was shown to block C5 cleavage in vitro (Wurzner et al 1991) . Subsequently, a second antibody to human C5, termed h5G1.1, was developed (Kroshus et al 1995) . This molecule was modifi ed to have only single-chain Fv fragments but still retain full antiC5 activity (Thomas et al 1996) .
Using recombinant DNA technologies, investigators became able to combine complement-binding antibodies to inhibitory domains of complement regulatory proteins. There are two different ways in which these hybrid molecules have been designed. One way is to use the F ab portion (the antigenbinding fraction) of the antibody to direct the molecule toward a particular cell membrane component, while the F c portion (the constant fraction) is the soluble complement regulator itself. Two examples of hybrid molecules created in this way are antidansyl F ab arms fused with either CD59 or DAF (Zhang et al 1999 (Zhang et al , 2001 ). Both fusion proteins were able to avidly bind to dansyl-labeled Chinese hamster ovary cells. Another way to fuse antibody fragments to soluble complement inhibitors is to use the complement inhibitors themselves as the F ab arms of the molecule and to use the normal F c portion of the antibody to keep the molecules in the circulation longer (Pugsley 2001) . One downside to this approach is reduced activity of the hybrid molecule as compared to a pure soluble complement inhibitor, perhaps due to a steric hindrance (Harris et al 2002) .
Complement inhibition as therapy for disease
The possibility of complement inhibition as therapy for various disease states has been studied in organ transplantation, ischemia-reperfusion injury, coronary artery disease, myocardial infarction, stroke, infection, cancer, immunosuppression, paroxysmal nocturnal hematuria, glomerulonephritis, rheumatoid arthritis, and acute respiratory distress syndrome, and has also been used in the coating of extracorporeal circuits in cardiopulmonary bypass and dialysis (Table 1) . Any possible benefi t from inhibiting the complement system should be balanced with potential side effects, such as an increased susceptibility to infection with encapsulated bacteria, Neisseria meningitidis in particular, and autoimmune diseases caused by decreased clearance of immune complexes. In this review, we will focus on anticomplement therapy in paroxysmal nocturnal hemoglobinuria, glomerulonephritis, coronary artery disease, myocardial infarction, and cardiac surgery requiring cardiopulmonary bypass.
Paroxysmal nocturnal hemoglobinuria Overview and pathophysiology
Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal disorder due to an acquired somatic mutation in the X-linked phosphatidylinositol glycan complementation class A (PIG-A) gene, which leads to a partial or complete defi ciency of all proteins which are usually linked to the cell membrane via a glycosyl phosphatidylinositol (GPI) anchor (Takeda et al 1993; Bessler et al 1994) . DAF and CD59, complement regulatory proteins, are two GPI-anchored molecules; therefore, PNH cells have a deficiency of DAF and/or CD59 on their cell membrane and are more susceptible to destruction by complement. The proportion of normal stem cells and PNH stem cells in any one patient can vary, but PNH cells usually constitute the majority of hematopoietic cells . The clinical features of PNH include intravascular hemolysis, bone marrow failure, and a predisposition to thrombosis (Hillmen et al 1995; Socie et al 1996) . Patients usually have acute severe hemolytic episodes with a chronic mild hemolysis in the background . Despite the extensive hemolysis, the major cause of morbidity and mortality in PNH is venous thrombosis, which occurs in about 50% of patients and is responsible for one-third of deaths in PNH (Hillmen et al 1995; Socie et al 1996) . The cause of PNH patients' predilection to thrombosis is currently unknown . While venous thrombosis is the major cause of morbidity and mortality in PNH, many patients also develop pancytopenia due to aplastic anemia . The median survival of patients with PNH from the time of diagnosis is about 10-15 years. However, approximately 15% of patients experience spontaneous regression of PNH with no residual sequelae (Hillmen et al 1995) .
Therapy
Standard therapy for PNH includes supportive care with red blood cell (RBC) transfusions and treatment of thrombotic complications . The only defi nitive cure for PNH currently is allogeneic bone marrow transplantation (BMT), with indications for this similar to the indications for BMT in aplastic anemia.
In the past several years, studies have been conducted on the humanized monoclonal antibody eculizumab (Alexion Pharmaceuticals, Soliris, Cheshire, Connecticut, USA), which is directed against human C5 (Thomas et al 1996) . In 2004, a pilot study using 11 patients with PNH was conducted in which the patients received infusions of eculizumab over a period of 12 weeks (Hillmen et al 2004) . In this small study, mean lactate dehydrogenase (LDH) levels decreased signifi cantly over the course of the study; the percentage of PNH erythrocytes increased signifi cantly; transfusion rates declined; and the occurrence of hemoglobinuria subsided dramatically. All of the patients from this study chose to participate in a 52-week extension of the study, in which they received eculizumab infusions every 12-14 days (Hill et al 2005a) . The fi ndings from the initial pilot study all held up during the follow-up study, with the addition of quality-oflife measurements being signifi cantly improved. It was also shown through this study that long-term eculizumab therapy is safe and well tolerated. In a study of two patients treated with eculizumab, intravascular hemolysis decreased, and symptoms associated with smooth muscle dystonia, such as abdominal pain, dysphagia, and erectile dysfunction, were also signifi cantly reduced (Hill et al 2005b) .
All of this work provided the impetus for a future study involving larger numbers of patients in a double-blind, randomized, placebo-controlled phase III trial, termed the Transfusion Reduction Effi cacy and Safety Clinical Investigation, a Randomized, Multicenter, Double-Blind, PlaceboControlled, Using Eculizumab in Paroxysmal Nocturnal Hemoglobinuria (TRIUMPH) study (Hillmen et al 2006) . Eighty-seven patients were given either 600 mg eculizumab or placebo on a weekly basis for 4 weeks, then a 900 mg dose one week later, then 900 mg every other week up to 26 weeks. The primary end points were the hemoglobin level and how many units of blood the patients needed during the period of time of the study. Hemoglobin stabilization without transfusion occurred in 21 of 43 patients in the eculizumab group, while it occurred in 0 of 44 patients in the placebo group. A median of 10 units of blood were given to the placebo group during the study period, while the group receiving eculizumab required 0 units. In addition, the eculizumab group had a signifi cant decrease in LDH levels as well as a signifi cant increase in quality of life.
In a multinational open-label extension study of the TRI-UMPH study using 195 patients, the same authors studied the effect of eculizumab on the occurrence of thromboembolism (TE) . Prior to treatment, the TE event rate was 7.37/100 patient-years, whereas with treatment, the rate was 1.07/100 patient-years. It was thus concluded that treatment with eculizumab in PNH signifi cantly reduces the occurrence of TE.
Another possible option for the treatment of PNH is recombinant soluble CD59, since this is one of the critical membrane-bound proteins defi cient in PNH. In vitro studies with human PNH erythrocytes showed that recombinant soluble CD59 was able to bind to the surface of RBCs at levels suffi cient to inhibit complement-mediated hemolysis (Hill et al 2006) . In an in vivo experiment, the RBCs of mice given recombinant soluble CD59 were partially protected from complement-mediated destruction. In a similar experiment, a single-chain antibody variable region fragment targeted against TER-119, a mouse RBC antigen, was attached to human DAF (Spitzer et al 2004) . This recombinant protein was able to bind to mouse RBCs in vivo and protect them from complement-mediated destruction.
Glomerulonephritis Overview and pathophysiology
The basic pathophysiology of glomerulonephritis is inflammation of the glomerulus, and the main clinical features of the various glomerulonephritides include proteinuria, hematuria, and decreased glomerular function (Javaid and Quigg 2005) . End-stage renal disease can be the eventual outcome of glomerulonephritis, which leaves patients dependent on chronic dialysis and/or renal transplantation.
The complement system can play a signifi cant role in the infl ammation of glomerulonephritis. For example, greater than 80% of patients with Type II membranoproliferative glomerulonephritis (MPGN) are positive for serum C3-nephritic factor, an antibody against C3bBb which inhibits the dissociation of Bb from C3b (Daha et al 1976; Schwertz et al 2001) . In patients with IgM nephropathy, serum C3 levels are directly correlated with proteinuria and progression of the disease (Myllymäki et al 2006) .
The important role of the complement system in the development of different glomerular diseases has been shown in several animal models. Mice defi cient in FH develop Type II MPGN with deposition of C3 in the capillary walls . Of interest, mice defi cient in FH and C5 developed less severe disease than those only defi cient in FH (Pickering et al 2006) .
Mice deficient in either DAF or DAF and CD59 had an increased incidence of immune-complexmediated glomerulonephritis with increased glomerular deposition of C3 (Bao et al 2007) . In a mouse model of immune-complex-mediated glomerulonephritis, CD59-deficient mice had more proteinuria (Turnberg et al 2003) . Similarly, DAF-deficient mice and DAFand CD59-combined knockout mice had much worse albuminuria in a model of nephrotoxic serum-induced nephritis (Lin et al 2004) .
In another mouse model of progressive glomerlonephritis, C5a receptor (C5aR)-defi cient mice showed less interstitial damage than control mice (Welch et al 2002) . Similarly, in a mouse model of lupus nephritis, a synthetic anti-C5a receptor molecule (a cyclic hexapeptide) led to less decline in renal function, as well as decreased infi ltration of kidneys by neutrophils and macrophages (Bao et al 2005) .
Despite the etiologic role of the complement system in the pathogenesis of the majority of the glomerulonephritides, in some cases, a functional complement system might play a protective role against the development of glomerulonephritis. For example, factor D-deficient mice, which lack the alternative complement system, developed immune-complex glomerulonephritis (specifically Type II rapidly progressive glomerulonephritis) and showed mesangial deposition of IgM (Abrera-Abeleda et al 2007). Complement activity is necessary for the clearance of immune complexes from the body, and lack of this clearance activity due to a deficiency in complement activity might contribute to the development of glomerulonephritis. Another example of complement's protective role in glomerulonephritis is that deficiencies in C1q, C2, or C4 predispose humans to the development of systemic lupus erythematosus (SLE) and lupus nephritis (Mitchell et al 2002) . Presence of anti-C1q antibodies, resulting in the lack of a functional classical complement pathway, predicts with relatively high sensitivity and specificity the presence of active lupus nephritis (Moroni et al 2001; Trendelenburg et al 2006) .
Anticomplement therapy
Anti-C1q antibodies are present in 30%-40% of patients with SLE (Seelen et al 2003) .
One might conclude based on these various, then, that the early components of the complement system are probably necessary for normal homeostasis of the immune system and that their absence may predispose to the development of immune-complex disease. Thus, targeting later components of the complement system for anticomplement therapy in glomerulonephritis may be the best option (Berger and Daha 2007) .
Therapy
The clinical trials of anticomplement agents in patients with kidney disease have been much more limited than those in PNH patients. Nonetheless, many in vitro experiments and animal studies have been conducted in various types of glomerulonephritis. Couser et al studied complement inhibition in three different animal models of complementmediated glomerulonephritis (Couser et al 1995) . In these models, administration of sCR1 was able to reduce the morphologic and functional characteristics of renal disease, as measured by mesangiolysis, glomerular infi ltration by platelets and macrophages, and proteinuria.
In a mouse model of immune-complex-mediated glomerulonephritis, a monoclonal antibody against C5, BB5.1, was able to lessen renal disease and prolong survival (Wang et al 1996) . The same antibody was also able to reduce proteinuria and renal damage in mice subjected to human antidouble-stranded DNA (Ravirajan et al 2004) . In a mouse model of antimyeloperoxidase IgG-induced glomerulonephritis, administration of anti-C5 antibody (BB5.1) thwarted the development of glomerular disease, as shown by decreased hematuria, pyuria, albuminuria, and glomerular neutrophil infi ltration (Huugen et al 2007) .
In a multicenter, randomized, placebo-controlled phase II trial conducted in the US on 122 patients with idiopathic membranous nephropathy, treatment with eculizumab did not decrease urinary protein excretion, the primary outcome goal of the study (Appel et al 2002) . However, there was some benefi t with eculizumab in the open-label extension of the study. Currently, there is an ongoing trial with eculizumab in patients with membranous nephropathy; the results of this trial are still pending (Berger et al 2005; Javaid and Quigg 2005; Brown et al 2007) .
Coronary heart disease
Coronary artery disease (CAD) is one of the most common causes of morbidity and mortality in the United States and the world at large. A signifi cant amount of work has been done to better understand the role of the complement system in the pathology and pathophysiology of atherosclerosis and myocardial infarction (MI). This work has culminated in several clinical trials which have tested anticomplement therapy in the setting of acute myocardial infarction (AMI) and cardiac surgery.
Stable coronary artery disease Overview and pathophysiology
It has long been known that the complement system is involved in the development of CAD. For example, even in the late 1970's and throughout the 1980's, it was repeatedly shown that C3 is present in atherosclerotic plaques (Hollander et al 1979; Hansson et al 1984; Vlaicu et al 1985) . Interestingly, complement regulatory proteins, including CR1, complement receptor 3, DAF, and CD59 are also present in atherosclerotic plaques, thus demonstrating activity and regulation of the complement system in atherosclerotic plaques Hansson 1989a, 1989b; Seifert et al 1992) .
More recently, it was shown that C3 levels may be a good marker of insulin resistance, a risk factor for the development of diabetes mellitus (DM), and CAD (Muscari et al 2000) . The level of C3 was a better predictor of blood pressure and glucose levels than the level of insulin itself. C3 levels also have an independent, signifi cant correlation with fi brinogen levels, body mass indices, platelet counts (important for the development of thrombi), insulin levels, triglyceride (TG) levels, and levels of low-density lipoprotein cholesterol (Capuano et al 2006) .
To our knowledge, no clinical trials using anticomplement therapies have been conducted in patients with stable CAD. However, we describe this work because it is relevant to potential clinical studies that could be done in patients with CAD.
Acute myocardial infarction Overview and pathophysiology
Involvement of the complement system in AMI has been shown since the 1970's. It was fi rst observed that administration of CVF 30 min prior to occlusion of the left anterior descending coronary artery in dogs reduced necrosis and neutrophil infi ltration into the myocardium (Maroko et al 1978) . The complement proteins C3, C4, and C5 were deposited on infarcted tissue in a baboon model of AMI, and Laine et al showed that there was extensive deposition of iC3b in ruptured plaques, as compared to nonruptured plaques, from human coronary arteries in patients who had died from AMI (Pinckard et al 1980; McManus et al 1983; Laine et al 2002) .
Patients with MI have increased post-infarction plasma levels of C5b-9 (Langlois and Gawryl 1988) . Actually, levels of C3, C8, C9, and FB were all signifi cantly increased in patients 6 and 12 hours after admission for MI (Halas et al 2005) . C5b-9 was also found to be present in higher quantities in pathologic specimens of atherosclerotic plaques from patients with acute coronary syndrome (ACS) as compared to those with stable angina (Meuwissen et al 2006) . Interestingly, the presence of C5b-9 in necrotic tissue was associated with the loss of CD59 in postmortem studies on patients who died from MI (Väkevä et al 1992) .
Recently, several complement proteins have been studied as predictive markers in CAD leading to MI. For example, there was a substantial correlation between C3 levels and several cardiovascular risk factors, such as blood pressure, body mass index, and serum lipid levels (Engström et al 2007) . C3 levels were shown to be a strong predictor of MI, especially in men, and C3a levels were elevated in patients with unstable angina as compared to those with stable angina (Muscari et al 1995; Kostner et al 2006) . Finally, C3 and C4 levels in patients admitted for AMI were signifi cantly higher than in patients with stable angina or healthy controls, and the serum C3/C4 ratio could possibly be used as a marker of subsequent cardiovascular events after a previous manifestation of ACS (Iltumur et al 2005; Palikhe et al 2007) . Additionally, elevated C5a levels were shown to be associated with an increased risk of MI, PCIs, coronary artery bypass graft (CABG) surgery, carotid revascularization, stroke, or death in patients with advanced atherosclerosis (Speidl et al 2005) .
C-reactive protein (CRP) interacts with the complement system. It was shown that CRP binds to damaged cardiomyocytes and activates the complement system Siegel et al 1974; Volanakis and Kaplan 1974; Volanakis 1982; Jiang et al 1992) . The level of deposited CRP correlated with the extent of activation of the complement system in infarcted myocardial tissue as determined by measuring levels of complement proteins, CRP, and CRP-complement protein complexes (Nijmeijer et al 2003) . In a rat model of MI, injection of human CRP increased the size of infarcted myocardial tissue. This effect of CRP was blocked by CVF-induced complement depletion even two hours after induction of MI (Griselli et al 1999) .
The mainstay of treatment for MI is early revascularization through thrombolytic therapy, percutaneous coronary intervention (PCI), or CABG surgery. However, revascularization carries with it the risk of ischemia-reperfusion injury, in which the complement system is activated. Reperfusion has been known to cause arrhythmias, microvascular dysfunction, and even cell death (Verma et al 2002) . Reperfusion can also cause a condition known as myocardial stunning, which refers to diminished contractility of ischemic but still viable myocardium after full revascularization (Braunwald and Kloner 1982) . The complement system has been shown to be involved in the acute infl ammatory response associated with ischemia-reperfusion injury (Yasuda et al 1990; Eltzschig and Collard 2004) . Activation of the complement system increases vascular permeability, activates endothelial and infl ammatory cells, coagulates blood, and causes cell lysis.
Therapy
Several anticomplement therapies have been tried in different animal models of MI and ischemia-reperfusion, as well as in human clinical trials. One of the fi rst anticomplement reagents used was the soluble form of complement receptor 1 (sCR1), a recombinant protein that comprises the extracellular part of the complement regulatory protein CR1. In an isolated rat model of ischemia-reperfusion injury, sCR1 was able to prevent post-ischemic myocardial contractile dysfunction and enhance coronary blood fl ow (Shandelya et al 1993) . sCR1 modifi ed with the addition of a myristoylated peptide sequence, creating a molecule known as Mirococept and giving sCR1 the ability to bind to cell membranes, decreased infarct size, reduced serum troponin I, and resulted in a lower amount of complement deposition and myocardial apoptosis in a pig model of AMI (Banz et al 2007) .
C1-INH has also been used with some success in different models of MI and ischemia-reperfusion. In a cat model of ischemia-reperfusion, C1-INH given just before reperfusion reduced infarct size by 65% (Buerke et al 1995) . In a rat model of MI, C1-INH suppressed C3 mRNA expression and protein synthesis, while in cultured rat cardiomyocytes, C1-INH blocked deposition of C3 (Fu et al 2006b) . In the same model of MI in rats, C1-INH protected against cardiomyocyte apoptosis, improved cardiac function, reduced infarct size, and decreased infi ltration by neutrophils (Fu et al 2006a) .
Treatment with C1-INH has also been studied in patients with MI. In one study, 22 patients received a loading dose of C1-INH followed by a continuous 48-hour infusion at least 6 hours after the onset of symptoms (de Zwaan et al 2002) . In this small study, a C1-INH dose-dependent reduction in activation fragments of C4 was shown. In 13 of the 16 patients who received thrombolytic therapy and C1-INH, the values of troponin T and creatine kinase-MB (CK-MB) were reduced by 36% and 57%, respectively, as compared to 18 control patients who had AMI and did not receive C1-INH therapy.
The other component of the complement cascade that has been the target of anticomplement therapy in MI is C5. In a dog model of cardiac ischemia induced by ligation of the left circumfl ex artery, cardiac lymph obtained from the dogs several hours after reperfusion was able to activate neutrophils (Dreyer et al 1992) . However, this effect was completely abolished when anti-C5a was added to the cardiac lymph. It was also shown that the monocyte chemotactic activity of cardiac lymph in the fi rst few hours after reperfusion is almost completely due to C5a (Birdsall et al 1997) . More directly, in a porcine model of ischemia-reperfusion, a recombinant human C5 antagonist, CGS 32359, was able to inhibit neutrophil activation and reduce infarct size (Riley et al 2000) . Finally, in a rat model of ischemia-reperfusion, a monoclonal antibody against C5 reduced apoptosis, necrosis, and neutrophil infi ltration (Vakeva et al 1998) .
A large randomized, placebo-controlled phase II study of 960 patients, the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial, investigated the effect of anti-C5 therapy in AMI . In this study, the anti-C5 agent pexelizumab (Alexion Pharmaceuticals, Cheshire, Connecticut, USA) was used. Patients with AMI who underwent primary PCI therapy were randomized to placebo, pexelizumab bolus given just before revascularization, and pexelizumab bolus plus subsequent infusion for 20 hours. There was no difference between the groups with respect to infarct size as determined by CK-MB area under the curve (AUC), but there was a signifi cant benefi t in 90-day mortality rate for the bolus plus infusion group (1.8%) as compared to the placebo group (5.9%).
In a substudy of the COMMA trial, there was a signifi cant difference in the hemodynamic status of the groups treated with pexelizumab versus placebo after correcting for age, race, and MI location (Armstrong et al 2006) . It was shown that this improved hemodynamic status was not due to infarct size, degree of ST-segment elevation, or extent of reperfusion. In another substudy of the COMMA trial, it was shown that higher CRP and interleukin-6 (IL-6) levels at baseline, 24 hours, and 72 hours were associated with increased death, and that elevated CRP, IL-6, and tumor necrosis factor-α levels were associated with more cardiogenic shock or death within 90 days of treatment (Théroux et al 2005) . Despite similar serum levels of CRP and IL-6 at baseline, the pexelizumab-treated groups had signifi cantly lower CRP and IL-6 levels at 24 hours, but by 72 hours, the values were similar between different groups.
The COMMA trial was the fi rst part of a two-part phase II clinical trial called the Complement And ReDuction of INfarct size after Angioplasty or Lytics (CARDINAL) program. The results of the second part of the CARDINAL study, known as the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial, were also reported in 2003 . In this study, 943 patients who underwent fi brinolysis for ST-segment elevation MI (STEMI) were randomized similarly to the way patients were randomized in the COMMA trial. It was shown that pexelizumab lowered complement activity but had no effect on infarct size as measured by CK-MB AUC or on adverse clinical outcomes in the 90 days following treatment.
The follow-up to the CARDINAL program was a large, prospective, multicenter, randomized, double-blind, placebocontrolled phase III trial in which 5745 patients who had a STEMI treated with PCI were randomized to either placebo or treatment with pexelizumab as a bolus just before PCI and then as a 24-hour infusion after revascularization therapy (APEX AMI Investigators et al 2007). This trial showed no difference in 30-day all-cause mortality or in the 90-day composite of death, cardiogenic shock, or congestive heart failure.
Coronary artery bypass graft surgery, ischemia-reperfusion injury, and cardiopulmonary bypass After revascularization with emergent CABG surgery in the setting of AMI, reperfusion can activate the complement system, similar to reperfusion with thrombolysis or angioplasty. Also, in cardiac surgery, use of cardiopulmonary bypass (CPB) exposes blood to nonself material in extracorporeal circuits, which in turn activate the alternative complement system. Thus, inhibition of complement activity may be benefi cial in decreasing infl ammation and tissue injury resulting from CABG surgery through two mechanisms, prevention of revascularization injury and reduced activation of the complement system associated with exposure of blood to extracorporeal circuits.
The effect of C1-INH was studied in 67 patients who underwent emergency CABG surgery for STEMI (Thielmann et al 2006) . In this study, a bolus of C1-INH was given during, and another bolus given 6 hours after, surgery. It was shown that if C1-INH was given within 6 hours of the onset of symptoms, troponin I levels were reduced, but administration of C1-INH between 6 and 24 hours after the onset of symptoms failed to decrease troponin I levels. There was no difference between patients who received C1-INH and those who did not with respect to the length of hospital or intensive care unit (ICU) stays, post-operative complications, or in-hospital mortality, regardless of the initiation time of C1-INH infusion.
In another randomized, double-blind, placebo-controlled study, 80 patients with STEMI who underwent emergent CABG surgery were enrolled, with half receiving C1-INH and the other half receiving only a saline solution (Fattouch et al 2007) . Patients received a bolus of C1-INH 10 min before reperfusion and then an intravenous infusion for 3 hours after surgery. Those receiving C1-INH showed a benefi t in the amount of inotrope drugs required, intubation time, length of ICU stay, and various measures of cardiac function, such as mean arterial pressure, cardiac index, and stroke volume. The levels of troponin I after reperfusion were signifi cantly lower in the C1-INH group as compared to the placebo group. However, the rate of early mortality was not signifi cantly different between the two groups.
In one study of 564 patients, TP10 (a recombinant sCR1) or placebo was given to high-risk patients undergoing cardiac surgery requiring CPB (Lazar et al 2004) . TP10 inhibited the complement system after 10-15 min of CPB, an inhibition which persisted until post-operative day (POD) 3. The primary endpoint in this study was death, MI, prolonged intra-aortic balloon pump support, and prolonged intubation. The TP10 group showed a lower primary endpoint event rate by 30% only in male patients. In a follow-up study of 297 female patients randomized to treatment with TP10 or placebo, it was shown that TP10 suppressed complement activation but did not reduce the incidence of death or MI by 28 days after surgery (Lazar et al 2007) . A possible reason for this lack of difference is that the number of adverse events in the control arm of this trial was quite low to begin with, at 17%. Therefore, it became diffi cult to prove any statistical difference with only 297 patients. Thus, the study size combined with the low event rate in the placebo group together made it diffi cult to show any benefi cial effect of TP10.
Heparin, as mentioned earlier, has long been known to possess anticomplement activity. In a pig model of ischemia-reperfusion, 40 pigs were studied: 10 pigs received sCR1, 10 underwent surgery with heparin-bonded CPB (HB-CPB) circuits, 10 received sCR1 and underwent surgery with HB-CPB circuits, and 10 neither received sCR1 nor underwent surgery with HB-CPB circuits (Lazar et al 1999) . As expected, sCR1 combined with the use of HB-CPB circuits led to less myocardial tissue acidosis, better recovery of wall motion, less pulmonary edema, and smaller infarct size.
In a human trial, the effect of heparin on complement activation was studied in 151 patients undergoing cardiac surgery. Heparin coating of CBP circuits reduced complement activation, especially C5b-9 formation, but did not reduce the release of the neutrophil granule enzymes myeloperoxidase and lactoferrin (Fosse et al 1997) .
Pexelizumab has also been studied in patients undergoing cardiac surgery requiring CPB. One of the fi rst studies conducted was a prospective, open-label, randomized phase I study in 17 patients who underwent primary, nonemergent CABG surgery with CPB. In the fi rst phase of the study, patients were randomized to receive escalating doses of h5G1.1-scFv (not yet known as pexelizumab) (Fitch et al 1999) . In another part of the study, 18 patients were randomized into 3 groups and received placebo or one of two different doses of h5G1.1-scFv. It was shown that leukocyte activation, determined by expression of CD11b, was reduced in patients receiving the higher doses of h5G1.1-scFv. In those patients receiving the highest dose of h5G1.1-scFv (2 mg/kg), a 40% reduction in CK-MB was observed. In addition, in patients treated with the highest dose of h5G1.1-scFv, there was an 80% reduction in new cognitive defi cits as determined by sequential mini-mental status exams.
In a follow-up to this study, a randomized, double-blind, placebo-controlled multicenter phase II trial in patients who underwent nonemergent CABG surgery with or without concomitant valve surgery, participants were randomized into three groups, those receiving placebo, those receiving a pexelizumab bolus, and those receiving a pexelizumab bolus and subsequent infusion . It was shown that giving pexelizumab as a bolus plus infusion reduced the composite of death or MI in patients undergoing CABG surgery only without valve surgery on POD 4 and POD 30. There was, however, no difference in the primary endpoint, namely the composite of death, new MI, left ventricular dysfunction, or new neurological events, between the two groups overall.
This phase II trial was further analyzed from the neurological perspective in a follow-up substudy (Mathew et al 2004) . Neurological and neurocognitive functions were assessed on POD 4 and POD 30 in patients enrolled in the substudy. Pexelizumab had no effect on overall cognition on either day. The only difference was in visuo-spatial function, which was signifi cantly better in the treated group as compared to the placebo group on POD 4 and POD 30. This phase II trial was followed up with a larger phase III, randomized, double-blind, placebo-controlled, multicenter study of 3099 patients undergoing nonemergent CABG surgery with or without valve surgery (Verrier et al 2004) . In this study, termed the Pexelizumab for Reduction in Infarction and MOrtality in Coronary Artery Bypass Graft surgery (PRIMO-CABG) trial, patients were randomized into two groups, one receiving an intravenous bolus of pexelizumab plus a subsequent 24-hour infusion and the other receiving placebo. The primary endpoint in this trial was the composite of death or MI within 30 days of surgery. This large, extensive study did not show any signifi cant difference between the two groups with regard to the incidence of death or MI at 30 days, with the event rate being 9.8% (134/1373) in patients who received pexelizumab and 11.8% (161/1359) in patients who received placebo (p = 0.07).
In a substudy of the PRIMO-CABG trial, it was shown that pexelizumab reduced the incidence of death or MI by POD 30 by 28% in patients with two or more risk factors, including DM, prior CABG surgery, urgent intervention, female sex, history of a neurological event, CHF, two or more previous MIs, or a recent MI (Haverich et al 2006) . In separate follow-up analysis, a subgroup of patients with aortic cross-clamp times Ͼ90 min showed reduced perioperative myocardial injury (Smith et al 2006) . Of this specifi c subset of patients, those with two or more serious cardiovascular risk factors had a reduced incidence of death or MI through POD 30 and a signifi cantly reduced incidence of mortality 180 days after surgery.
In one final substudy analysis of patients in the PRIMO-CABG trial, pexelizumab reduced mortality at 180 days in patients who underwent aortic valve replacement (AVR) at the time of CABG surgery . However, both mortality and the incidence of MI at 30 days were not signifi cantly different between those who had an AVR with their CABG surgery and those who did not.
In a broad meta-analysis of the four large trials with pexelizumab described above (COMMA, COMPLY, Phase II CABG study, and PRIMO-CABG), using data from 5916 patients who either had an AMI treated with PCI or thrombolytic therapy or who underwent CABG surgery, it was shown that pexelizumab reduced 30-day mortality when given as a bolus followed by subsequent infusion .
The angioplasty, thrombolytic, and CABG surgery trials involving anticomplement therapy did not provide as much benefi t to patients as had been hoped for. We can only speculate about why the in vitro and animal studies did not translate to successful therapeutic results in human trials; however, advances in the complement science and in understanding of thrombotic disorders will provide the real answers.
Future directions
In addition to the clinical applications described in the previous section, there are two other main clinical conditions with potential therapeutic roles for complement regulatory proteins.
Sepsis
There are several studies reporting an increase in complement activation products (C5a, C3a, C5b-9) in animal models of sepsis, as well as in patients with sepsis and multiorgan system failure (Ward 2008) . For example, in the setting of experimental sepsis in mice or rats induced by cecal ligation and puncture, there is an upregulation of C5a receptor (C5aR) in solid organs and on the surface of neutrophils (Riedemann et al 2002; Ward 2008) . Despite an increase in the concentration of C5a, the normal functions of neutrophils, including chemotaxis, phagocytosis, and oxidative burst, are impaired during sepsis (Huber-Lang et al 2002b) . These abnormalities in neutrophil function are probably due to a paralysis of C5a signaling (Ward 2008) . Using anti-C5a antibody or anti-C5aR cyclic peptide can reverse neutrophil paralysis and, more importantly, can increase survival in animals with severe sepsis (Huber-Lang et al 2001 , 2002a . To date, no trials using anti-C5a antibody or anti-C5aR agents have been performed in patients with sepsis.
Age-related macular degeneration
Age-related macular degeneration (AMD) is a leading cause of blindness among older individuals in developed countries. In 1998, a genome-wide screening study in a family with AMD identifi ed the long arm of chromosome 1 (1q25-q31) as the locus for the responsible gene (Klein et al 1998) . In 2005, three independent studies using different methods identifi ed an association between a polymorphism in factor H (Tyr402His) and AMD in the general population (Edwards et al 2005; Haines et al 2005; Klein et al 2005) . Later on, associations between AMD and additional polymorphisms in the factor H gene, as well as polymorphisms in other complement proteins, were detected (Gold et al 2006; Hughes et al 2006; Li et al 2006; Maller et al 2006; Dinu et al 2007) . Functional and anatomical studies conducted on factor H-deficient mice revealed a signifi cant reduction in visual acuity and abnormalities in electroretinography of factor H-defi cient mice as compared to control mice (Coffey et al 2007) . These functional abnormalities were associated with complement deposition and altered retinal structure. Studies using factor H purifi ed from serum and recombinant factor H showed decreased binding of the 402His variant of factor H to CRP and heparin as compared to the wild-type 402Tyr variant (Clark et al 2006; Laine et al 2007) . Despite the presence of strong data linking polymorphisms in factor H to retinal damage in AMD, further animal and human studies are required before this information may be applied to clinical use.
Conclusion
The fi eld of anticomplement therapy is a rapidly-evolving one and has much potential for future benefi t in clinical medicine. It will arguably have the most impact in the treatment of PNH, for which anticomplement therapy has been shown to be a highly effective treatment. As for the use of anticomplement therapy in the treatment of CAD and its complications, initial studies appeared promising, but larger, more extensive studies turned out to be more disappointing than had been desired. However, since the complement system is a complex, multifaceted system, there are potentially many more therapeutic targets that may be exploited in the future for the treatment of CAD, glomerulonephritis, sepsis, AMD, and many other diseases.
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